PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast: Recent Episodes
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.
Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid developments in AD assessment and treatment, it is vitally important to increase awareness of ARIA among healthcare providers. In this activity, based on a recent live symposium, AD experts pair compelling, real-world case scenarios with practice-changing evidence to illustrate how to select patients for treatment with ATTs, how to discuss the risk of ARIA with patients, and how to monitor, recognize, and manage ARIA in patients once they start treatment. Upon completion of this activity, participants should be better able to: Select appropriate patients for treatment with amyloid-targeting therapies (ATTs); Appropriately monitor for and manage amyloid-related imaging abnormalities (ARIA) in patients taking ATTs for the treatment of early-stage Alzheimer’s disease (AD); and Implement effective communication strategies to educate patients and caregivers about ARIA.
Go online to PeerView.com/FMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore recent advances in the management of cognitive impairment associated with schizophrenia (CIAS) and learn how to implement current and emerging treatment strategies into individualized care plans to improve your patients’ outcomes and quality of life. Upon completion of this activity, participants should be better able to: Summarize the burdens of cognitive impairment in patients with schizophrenia and its impact on patient outcomes and quality of life; Describe the pathophysiology of CIAS, emphasizing the difference between negative symptoms and cognitive impairment; and Implement current and emerging treatment strategies for CIAS, taking into account the latest evidence and patient treatment goals, preferences, and unmet needs.
Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD
Go online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment. At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment; Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS; and Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities]
Go online to PeerView.com/JHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies. In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes. Upon completion of this activity, participants should be better able to: Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response; Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics; and Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Go online to PeerView.com/MWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Jessica Ailani reviews the latest data on therapies for acute and preventive management of migraine, with a focus on personalized treatment. A patient interview and 3D animation are also part of this engaging video program. Upon completion of this activity, participants should be better able to: Apply safety and efficacy data related to new acute migraine therapies in clinical decision-making, taking into account patient-reported outcomes; Employ evidence-based prevention strategies for patients with migraine; and Implement individualized treatment plans for patients with migraine.
Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.
Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.
Go online to PeerView.com/VZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data. At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy. Upon completion of this activity, participants should be better able to: Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG); Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions; and Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing.
Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.
Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.
Go online to PeerView.com/FJH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated educational activity, an expert in chronic inflammatory demyelinating polyneuropathy (CIDP) discusses the diagnosis, assessment, treatment, and monitoring of the disease. A patient also shares her experiences living with and treating her CIDP. Upon completion of this activity, participants should be better able to: Apply guideline-directed criteria to diagnose chronic inflammatory demyelinating polyneuropathy (CIDP), including correct interpretation of electrodiagnostic findings; Incorporate evidence surrounding efficacy, safety, and tolerability of recommended pharmacotherapies (eg, corticosteroids, IVIg, SCIg, and plasma exchange) and shared decision-making into CIDP treatment planning; and Employ validated assessment tools to monitor treatment response and guide clinical decision-making.
Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options.
Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.
Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.
Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will provide practical guidance on how clinicians can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice. Upon completion of this activity, participants should be better able to: Describe the rationale for identifying patients at risk for Alzheimer’s disease (AD) early in the disease course, Utilize validated neuroimaging techniques and molecular biomarkers to make early and accurate neuropathological diagnoses of AD, Select appropriate AD patients who may benefit from novel disease-modifying therapies based on an understanding of their respective mechanisms of action, efficacy, and safety profiles.
Go online to PeerView.com/JWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the use of anti-CD20 monoclonal antibodies in the treatment of relapsing MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies used to treat relapsing forms of MS, Apply best practices and clinical evidence when using B cell–depleting therapies to optimize outcomes for patients with relapsing MS, Implement treatment plans designed to maximize COVID-19 vaccination efficacy in patients being treated for MS with anti-CD20 medications.
Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke, Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy.
Go online to PeerView.com/HYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s behavioral health shares a downloadable tool kit created for OB/GYNs and other clinicians to facilitate the screening, diagnosis, and treatment of postpartum depression (PPD) and to provide guidance on the use of shared decision-making strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Utilize validated screening tools and current clinical guidelines to facilitate the early diagnosis of PPD, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for PPD, Develop individualized treatment protocols for patients with PPD that incorporate evidence-based care and shared decision-making.
Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.
Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.
Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to include expanded and detailed recommendations for the use of dual antiplatelet therapy (DAPT), the combination of aspirin and clopidogrel or ticagrelor, to further reduce the risk of stroke. These guidelines also include specific recommendations for individuals with minor acute ischemic stroke (AIS) or a TIA. In this activity based on a recent satellite symposium in New Orleans, leading experts on stroke management highlight the current guideline recommendations and discuss the latest perspectives on DAPT before transitioning to patient case scenarios where each expert demonstrates how these advances can be translated into clinical practice to improve outcomes and reduce the risk of recurrent stroke, while accounting for bleeding risks, antiplatelet resistance, and patient adherence. Upon completion of this CE activity, participants will be able to: Identify individuals with AIS or TIA who are appropriate candidates for treatment with antiplatelet therapy to reduce the risk of recurrent stroke, Assess the benefits and risks of using P2Y12 inhibitors with aspirin as DAPT for the prevention of recurrent stroke, Apply DAPT with P2Y12 inhibitors in appropriate patients following symptom onset to reduce the risk of recurrent stroke, Employ patient-centered communication strategies to facilitate adherence to DAPT with P2Y12 inhibitors in appropriate patients with AIS or TIA to reduce the risk of recurrent stroke.
Go online to PeerView.com/TCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in MS discuss the rationale, evidence, and practical potential for BTK inhibitors in patient-centered MS care. Upon completion of this CE activity, participants will be able to: Describe the rationale for inhibiting Bruton’s tyrosine kinase (BTK) to treat multiple sclerosis (MS), Evaluate current evidence related to the efficacy and safety of BTK inhibitors in the treatment of MS, Identify patients who could benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.
Go online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associated with S1PR modulators based on the most recent clinical data,Apply the latest clinical data on S1PR modulators to individualized MS treatment plans
Go online to PeerView.com/KZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A multidisciplinary panel of experts discuss the expanding role of neuroimaging in the diagnosis and management of Alzheimer’s disease. Upon completion of this CE activity, participants will be able to: Assess the relative utility of the structural, functional, and molecular neuroimaging techniques used in AD diagnosis and management, Implement an evidence-based, guideline-directed approach to using neuroimaging to assess amyloid burden when confirming a diagnosis of AD or determining patient eligibility for use of amyloid-lowering therapy, Apply validated neuroimaging techniques and biomarkers to monitor for treatment response, disease progression, and ARIA or other adverse events in patients being treated for AD, Employ a patient-centered, multidisciplinary approach to patient care in AD
Go online to PeerView.com/JUV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.
Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient’s ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.
Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.
Go online to PeerView.com/RQP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses emerging treatment options for patients with amyotrophic lateral sclerosis. Upon completion of this CE activity, participants will be able to: Evaluate the mechanisms of action, efficacy, and safety of emerging ALS therapies, Identify the potential impact of emerging therapies on genetic testing and treatment guidelines in ALS, Discuss opportunities with patients to participate in clinical trials.
Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.
Go online to PeerView.com/ETX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in sleep medicine discusses recent guidelines and evidence presented at the SLEEP 2021, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, on the pharmacologic management of idiopathic hypersomnia (IH). Upon completion of this accredited CE activity, participants should be better able to: Employ currently recommended approaches and available assessment tools to identify and differentially diagnose patients with IH, Incorporate the latest guideline recommendations and evidence for approved and emerging pharmacotherapies to optimize the management of patients with IH, Evaluate the clinical potential of recent advances in the pharmacologic treatment of patients with IH.
Go online to PeerView.com/AFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Pompe disease discusses the presentation of infantile- and late-onset Pompe disease, as well as treatment via enzyme replacement therapy. Upon completion of this accredited CE activity, participants should be better able to: Employ recommended assessments, including newborn screening (NBS), clinical presentation, and appropriate tests, to diagnose Pompe disease in a timely manner, Apply current recommendations and evidence regarding use of enzyme replacement therapy in the interdisciplinary management of Pompe disease, Recognize the potential role of emerging enzyme-replacement therapies in the treatment of Pompe disease.
Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.
Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.
Go online to PeerView.com/BPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the management of motor complications in Parkinson’s disease. Upon completion of this accredited CE activity, participants should be better able to: Identify the need to adjust treatment for “off” episodes in Parkinson’s disease through symptom and therapy assessment and clear communication with patients and/or caregivers, Interpret evidence regarding on-demand treatment options and their role in the management of “off” episodes in Parkinson’s disease, Apply on-demand treatment options, based on current evidence, in the personalized management of “off” episodes in Parkinson’s disease.
Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.
Go online to PeerView.com/WEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss treatment with B-cell therapies in patients with multiple sclerosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Recognize the similarities and differences between anti-CD20 monoclonal antibodies available for the treatment of relapsing forms of MS, Analyze available evidence on investigational B-cell–targeting therapies, Employ a patient-centered approach to treatment selection for patients with MS based on their disease activity, treatment preferences and goals, and therapeutic options.
Go online to PeerView.com/EME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex. Upon completion of this activity, participants should be better able to: Utilize clinical and genetic diagnostic criteria to identify patients with tuberous sclerosis complex (TSC) early in the disease course, Employ updated consensus recommendations for the surveillance of patients with TSC throughout the course of their disease, Apply updated consensus recommendations for the management of patients with specific disease manifestations associated with TSC.
Go online to PeerView.com/VWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting. Upon completion of this accredited CE activity, participants should be better able to: Identify best practices and current recommendations for diagnosing patients with migraine, including risk-stratification strategies for performing a differential diagnosis in the emergency department (ED); Apply evidence-based criteria and screening tools to accurately diagnose patients presenting to the ED with migraine; Summarize data on the efficacy, safety, and tolerability of agents currently available for the acute treatment and prevention of migraine; Employ strategies to help coordinate outpatient care and integrate current therapies into personalized management plans for acute treatment and prevention of migraine.
Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.
Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.
Go online to PeerView.com/ZVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the role of B cells in MS pathogenesis and the use of anti-CD20 monoclonal antibodies in the management of relapsing forms of MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies in the treatment of relapsing forms of MS, Apply best practices and clinical evidence when using B-cell–depleting therapies to optimize outcomes for patients with relapsing MS.
Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.
Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. [Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics. Upon completion of this activity, participants should be better able to: Recognize the rationale for using Bruton tyrosine kinase (BTK) inhibitors to treat multiple sclerosis (MS), Summarize current evidence regarding the use of BTK inhibitors in the treatment of MS, Assess the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/MHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in anticoagulation and bleeding mitigation discuss evidence-based strategies for safe reversal of direct oral anticoagulant (DOAC) therapy.Upon completion of this activity, participants should be better able to: Review current guidance regarding appropriate and safe reversal of DOACs, Explain the mechanisms of action of current and emerging DOAC reversal agents and universal antidotes to factor Xa inhibitors, Critically evaluate recent clinical evidence regarding the efficacy and safety data pertaining to the use of current and emerging DOAC reversal agents.
Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.
Go online to PeerView.com/XVB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses early diagnosis and emerging targeted therapies in the treatment of patients with amyotrophic lateral sclerosis (ALS). Upon completion of this activity, participants should be better able to: Apply established criteria to detect and diagnose patients with amyotrophic lateral sclerosis (ALS) early in the disease course, Recognize common genetic mutations that can cause ALS in patients with and without a family history of ALS, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of ALS, Identify the potential impact of emerging therapies on the future management of genetic subtypes of ALS.
Go online to PeerView.com/JFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses new disease-modifying therapies for multiple sclerosis. Upon completion of this activity, participants should be better able to: Apply the latest efficacy, safety, and tolerability data for approved disease-modifying therapies in individualized management of patients with multiple sclerosis, Discuss emerging data for newly approved disease-modifying therapies for the treatment of multiple sclerosis.
Go online to PeerView.com/NXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances—in understanding of disease pathogenesis, emerging therapies, and new imaging approaches—have the potential to significantly improve care of individuals with multiple sclerosis (MS). The recognition of a central role for B lymphocytes in MS pathogenesis and development of two classes of therapeutic agents that target B cells—anti-CD20 antibodies and Bruton tyrosine kinase (BTK) inhibitors—facilitates the use of more novel disease-modifying therapies (DMTs). In addition, advances in imaging approaches can enhance diagnosis, disease monitoring, and treatment guidance. In this activity, based on a recent live webcast, our expert faculty will offer insight into the pathogenesis of MS, targeting B cells for the treatment of MS, and novel imaging approaches for monitoring disease status and treatment in relapsing MS. Upon completion of this activity, participants should be better able to: Summarize current perspectives on the roles of diverse cell types (eg, B and T lymphocytes, microglia, astrocytes) in the pathogenesis of relapsing MS, Apply individualized treatment regimens for relapsing MS by incorporating recent information on new and emerging therapies that target B lymphocytes, Compare available and novel imaging approaches for monitoring disease status and facilitating treatment decisions in relapsing MS.
Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.
Go online to PeerView.com/JGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the treatment of patients with Alzheimer’s disease. Upon completion of this activity, participants will be able to: Recognize the importance of screening for mild cognitive impairment to identify patients at risk for AD early in the disease course, Employ fluid and imaging biomarkers to make early, etiologically based diagnoses of AD, Assess novel mechanisms of action and clinical data of emerging late-stage treatments that target the underlying pathology of AD, Identify potential infrastructure changes that may be required to prepare for a new AD disease-modifying treatment.
Go online to PeerView.com/NZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses strategies for accurately diagnosing and treating patients with posterior circulation stroke. After participating in this activity, the learner will demonstrate the ability to: Differentiate the signs and symptoms of acute ischemic posterior circulation stroke from other conditions with which it might be confused, Perform stroke assessments that facilitate more rapid diagnosis of acute ischemic posterior circulation stroke, Compare the therapeutic characteristics of current and emerging thrombolytic agents for acute ischemic stroke.
Go online to PeerView.com/VTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is a debilitating, chronic inflammatory disease that is characterized by demyelination and neurodegeneration of the central nervous system. Efforts to provide effective treatments for individuals with MS have led to FDA approval of many disease-modifying therapies since 2010, including the sphingosine-1-phosphate receptor (S1PR) modulators. Newer-generation S1PR modulators have been developed to preferentially target receptors 1 and 5, with the goal of improving safety profiles, which is expected to make these agents better treatment options for more MS patients. Moreover, the S1PR modulators have demonstrated a range of therapeutic benefits, including effects on gray matter atrophy. In this activity, based on a recent live webcast, our expert faculty offer insights into the role of S1PRs in the pathophysiology of MS and therapeutic benefits of S1PR modulators, including effects on brain atrophy metrics, in patients with MS. Upon completion of this activity, participants will be able to: Review the proposed mechanisms of action for sphingosine-1-phosphate receptor (S1PR) modulators and how they may address the pathophysiological defects associated with multiple sclerosis, Summarize key efficacy, safety, and tolerability data available for established, novel, and investigational S1PR modulators for the treatment of multiple sclerosis, Describe the therapeutic potential of current and emerging S1PR modulators for patients with multiple sclerosis, including impact on whole brain and gray matter atrophy metrics, Apply available evidence on established and novel S1PR modulators when managing patients with multiple sclerosis.
Go online to PeerView.com/JDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert narration is combined with 3D animation, patient video segments, and infographic visuals for an engaging presentation on individualized migraine management, including diagnosis and treatment, the role of 5-HT1F receptor agonists for acute treatment, and consideration of patient perspectives. Upon completion of this activity, participants should be better able to: Identify individuals with migraine, including those who are appropriate candidates for acute treatment, according to current treatment recommendations, Address unmet needs in acute treatment of people with migraine, Evaluate the role of 5-HT1F receptor agonists in meeting individual needs in acute treatment of migraine.
Go online to PeerView.com/EMM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry, neurology, and movement disorders discusses the recognition and management of tardive dyskinesia. Upon completion of this activity, participants should be better able to: Recognize the underlying pathophysiology of tardive dyskinesia, typical symptoms, and the burden on patient quality of life, Apply evidence-based criteria to differentially diagnose tardive dyskinesia from other hyperkinetic movement disorders, Employ the latest clinical evidence on efficacy and safety regarding the use of VMAT2 inhibitors to the management of patients with tardive dyskinesia.
Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients’ specific needs and circumstances.
Go online to PeerView.com/HNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses SMA presentation and progression, the importance of early SMA diagnosis, treatments approved for SMA, recommendations for symptomatic care, and methods for supporting patients with SMA and their caregivers. Upon completion of this activity, participants should be better able to: Recognize the role of newborn screening in overcoming diagnostic delays in spinal muscular atrophy, Apply current data on the efficacy, safety, and tolerability of approved therapies for the treatment of spinal muscular atrophy from infancy through adulthood, Identify how symptomatic monitoring and support may evolve in patients with spinal muscular atrophy over the course of their disease, Employ symptomatic care in conjunction with approved treatments to optimize outcomes in patients with spinal muscular atrophy.
Go online to PeerView.com/GMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses current guideline-based recommendations and therapeutic interventions to accurately identify and appropriately manage patients with an acute ischemic stroke. Upon completion of this activity, participants should be better able to: Describe the burden of acute ischemic stroke according to current standards of care from the perspective of the patient and the healthcare system, Identify patients with salvageable brain tissue using newer imaging technologies consistent with recommendations in recently updated evidence-based guidelines, To improve management of acute ischemic stroke, determine appropriate candidates to initiate timely therapeutic interventions in patients with suspected stroke.
Go online to PeerView.com/NDJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a stroke and vascular neurologist shares a patient case to provide clinical relevance and a practical exploration of the latest advances in the diagnosis and treatment of patients with a large hemispheric infarction (LHI). Upon completion of this activity, participants should be better able to: Apply current evidence-based guidelines to diagnose and treat patients with an LHI, Identify clinical characteristics associated with increased risk of cerebral edema in patients following an LHI, Summarize the benefits and limitations of current and emerging therapeutic strategies to prevent cerebral edema in patients following an LHI.
Go online to PeerView.com/HWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the diagnosis and treatment of spinal muscular atrophy in a new era of therapy. Upon completion of this activity, participants should be better able to: Employ current recommendations for screening and diagnosis of patients suspected to have spinal muscular atrophy (SMA), Recognize clinical signs and symptoms associated with early manifestations of SMA from birth to adulthood, Apply current data on the efficacy, safety, and tolerability of approved disease-modifying therapies for SMA from infancy through adulthood, Counsel patients and/or their parents/caregivers regarding the need for ongoing supportive care to optimize treatment outcomes.
Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.
Go online to PeerView.com/DKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multiple sclerosis expert discusses diagnosing, treating, and managing pediatric-onset multiple sclerosis. Upon completion of this activity, participants should be better able to: Identify patients with pediatric-onset multiple sclerosis according to their presenting symptoms and established criteria, Assess available data on approved disease-modifying therapies for the treatment of pediatric-onset multiple sclerosis, Select an appropriate course of disease-modifying therapy in individuals with pediatric- onset multiple sclerosis
Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy
Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/XXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in addiction medicine discusses opioid use disorder in the outpatient setting and overcoming the various barriers to patients receiving medication. Upon completion of this activity, participants should be better able to: Identify barriers to the implementation of medication-assisted treatment (MAT) for patients with opioid use disorder (OUD), Discuss the efficacy of treatment programs that include MAT for the management of OUD, Employ strategies to effectively and safely integrate MAT into the management of patients with OUD, to reduce opioid misuse and improve treatment retention, particularly in the outpatient setting
Go online to PeerView.com/PDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the diagnosis and management of patients with generalized tonic-clonic seizures. Upon completion of this activity, participants should be better able to: Differentiate generalized tonic-clonic seizures from other seizure types in patients with epilepsy, Recognize the significance of early antiepileptic drug treatment in patients with generalized tonic-clonic seizures, Cite current data on the efficacy and safety of approved therapies for the treatment of generalized tonic-clonic seizures, Apply available adjunctive strategies to manage treatment-resistance in patients with generalized tonic-clonic seizures
Go online to PeerView.com/HMV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert neurologist shares clinical pearls for accurately diagnosing and optimally treating patients with hereditary ATTR amyloidosis. Upon completion of this activity, participants should be better able to: Describe the common symptoms and underlying genetic mechanisms of hereditary ATTR amyloidosis, Apply genetic testing methods to accurately diagnose hereditary ATTR amyloidosis, Cite recent efficacy and safety data about available therapies for the management of hereditary ATTR amyloidosis, Employ approved therapies to reduce hospitalizations and mortality in patients with hereditary ATTR amyloidosis.
Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.
Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Cite current data on potential markers that may correlate with disease activity and severity and treatment response, Select an optimal course of disease-modifying therapy for individuals with MS according to their level of disease activity, preferences, and other factors.
Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.
Go online to PeerView.com/UGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.In this activity, experts in PKU discuss available adjunctive treatments, which provide an opportunity to lower blood Phe levels while potentially easing dietary restrictions and lessening the burden of this disease. Upon completion of this activity, participants should be better able to: Employ current practice guidelines and standards of care when managing individuals with phenylketonuria (PKU), Identify the challenges associated with dietary therapy in patients with PKU as they transition from childhood to adolescence and into adulthood, Describe the mechanisms of action of available adjunctive treatment approaches for the management of PKU, Assess available data on the efficacy, safety, and tolerability of approved adjunctive pharmacologic therapies for the management of adults with PKU, Apply available adjunctive therapies as part of a personalized approach to the management of adults with PKU.
Go online to PeerView.com/AKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses current and emerging interventions to reduce morbidity and mortality due to cerebral edema in patients with LHI. Upon completion of this activity, participants should be better able to: Apply evidence-based strategies for evaluation and management of large hemispheric infarction (LHI), Recognize the latest clinical trial data evaluating emerging therapy in the management of LHI and how this data applies to current practice
Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.
Go online to PeerView.com/XYB860 to view the entire program with slides. In this activity, an expert in the management of Lennox-Gastaut syndrome discusses the challenges of identifying, diagnosing, and treating patients with this condition. Upon completion of this activity, participants should be better able to: Identify patients with Lennox-Gastaut syndrome based on the presence of cardinal symptoms and hallmark features, Cite current data on approved pharmacologic therapies for the treatment of seizures associated with Lennox-Gastaut syndrome, Develop personalized seizure management regimens for patients with Lennox-Gastaut syndrome.
Go online to PeerView.com/PPP860 to view the entire program with slides. In this activity, an expert in multiple sclerosis discusses available disease-modifying therapies and strategies for shared decision-making for patients with multiple sclerosis. Upon completion of this activity, participants should be better able to: Recognize the mechanisms of action of disease-modifying therapeutic options for patients with multiple sclerosis, Apply available data on disease-modifying therapies when managing patients with multiple sclerosis, Employ evidence-based strategies designed to facilitate shared decision-making and maintain a therapeutic alliance with patients with multiple sclerosis.
Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?
Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?
Breaking Down the Barriers to Optimal Spinal Muscular Atrophy Care: Overcoming Diagnostic Delays, Facilitating Early Treatment, and Easing Caregiver Burden
Addressing the Evolving Opioid and HCV Epidemics Through Community Engagement and Education
Transforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era
Improving Long-Term Outcomes in Patients With Tardive Dyskinesia: Examining the Impact of New Therapeutic Options
Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?
Improving the Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention: How Is the Role of the Primary Care Clinician Evolving?
Expert Insights on Available and Emerging Therapies for the Management of Pompe Disease
Assessing the Role of Recent Therapeutic Breakthroughs in the Treatment of Amyotrophic Lateral Sclerosis